Some biotech investors had probably never heard of exosomes until Codiak’s chief executive, Doug Williams, made his pitch at the JP Morgan conference two weeks ago. But the area has been gaining traction, and Jazz’s $56m up-front...
Read More »Exosomes drive ‘fountain of youth’ found in cardiac stem cells
Cardiac stem cells derived from young hearts helped reverse the signs of aging when directly injected into the old hearts of elderly rats, a study published Monday in the European Heart Journal demonstrated. The old rats appeared newly invigorated after receiving their ...
Read More »Capricor Therapeutics Awarded Up to $4.2 Million from National Institutes of Health to Evaluate Exosomes for Hypoplastic Left Heart Syndrome
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company developing biological therapies for cardiac and other serious medical conditions, today announced that it has been awarded a grant of up to $4.2 million from the National Institutes of Health to ...
Read More »Exosome Therapeutics Developer Capricor (CAPR) Rating Increased to Buy at Zacks Investment Research
Capricor Therapeutics Inc (OTCMKTS:CAPR) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Tuesday, Analyst Ratings.Net reports. The brokerage currently has a $4.25 price objective ...
Read More »